New drug combo aims to slow advanced prostate cancer

NCT ID NCT05848011

Completed Disease control Sponsor: MacroGenics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate cancer will be randomly assigned to get either the combo or chemo alone. The main goal is to see if the combo delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lorigerlimab (an immunotherapy drug that targets PD-1 and CTLA-4) combined with docetaxel (chemotherapy) and prednisone (steroid)
What this could lead to: If successful, this combination could offer a new treatment option that delays disease progression in men with advanced prostate cancer that no longer responds to hormone therapy.
What could go wrong: This is a Phase 2 trial with only 154 participants, so results may not apply to all patients. Adding immunotherapy to chemotherapy can increase side effects like immune-related inflammation, and the benefit may be modest or not confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma hormone-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate carcinoma Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGEN-INDEPENDENT PROSTATIC CANCER ANDROGEN-INDEPENDENT PROSTATIC NEOPLASMS ANDROGEN-INSENSITIVE PROSTATIC CANCE ANDROGEN-RESISTANT PROSTATIC CANCER HORMONE REFRACTORY PROSTATIC CANCER IMMUNE CHECKPOINT INHIBITOR IMMUNOTHERAPY INHIBITORY CHECKPOINT MOLECULE PROSTATE CANCER - RECURRENT

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
CHP Saint Grégoire

Saint-Grégoire, France
CHU de Liège

Liège, Belgium
Centre Antoine Lacassagne

Nice, France
Centre Hospital de l'Ardenne

Libramont, Belgium
Centre Hospitalier Quimper

Quimper, France
Centre Léon Bérard

Lyon, France
Charing Cross Hospital

London, United Kingdom
Churchill Hospital

Headington, United Kingdom
Clinique Victor Hugo

Le Mans, France
Cliniques universitaires Saint-Luc (CUSL), Brussels

Brussels, Belgium
Comprehensive Cancer Center

Plovdiv, Bulgaria
Concord Repatriation General Hospital

Concord, Australia
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina

Otwock, Poland
FIVO: Instituto Valenciano de Oncología

Valencia, Spain
First University Clinic TSMU

Tbilisi, Georgia
H U Germans Tries i Pujol

Barcelona, Spain
Hia Begin

Saint-Mandé, France
Hopital Foch

Suresnes, France
Hospital 12 de octubre

Madrid, Spain
Hospital Clínic de Barcelona

Barcelona, Spain
Hospital Parc Tauli

Barcelona, Spain
Hospital Sant Pau

Barcelona, Spain
Hospital Universitario Virgen del Rocio

Seville, Spain
Hospital del Mar

Barcelona, Spain
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Institut Bergonie

Bordeaux, France
Institut Català d'Oncologia Hospitalet_ICO Hospitalet

Barcelona, Spain
Institut Gustave Roussy

Villejuif, France
Institut Mutualiste Montsouris

Paris, France
LTD Consilium Medulla

Tbilisi, Georgia
LTD High Tech Hosp Medcenter

Batumi, Georgia
LTD MMT Hospital

Tbilisi, Georgia
LTD Todua Clinic

Tbilisi, Georgia
LtD L.M.National Urology Center

Tbilisi, Georgia
Ltd Gidmedi

Tbilisi, Georgia
LuxMed Onkologia

Warsaw, Poland
MD Anderson Cancer Center

Houston, Texas, 77030, United States
MHAT Dr. Tota Venkova

Gabrovo, Bulgaria
Medical Concierge

Warsaw, Poland
Musgrove Park Hospital

Taunton, United Kingdom
Nebraska Cancer Specialists

Grand Island, Nebraska, 68803, United States
North Shore Private Hospital

St Leonards, Australia
Onc. Scient. Research Center

Tbilisi, Georgia
Orlando Health Cancer Institute

Orlando, Florida, 32806, United States
Pan American Center for Oncology Trials, LLC

Rio Piedras, Puerto Rico
Peter MacCallum Cancer Centre

North Melbourne, Australia
Pratia McM Kraków

Krakow, Poland
Przychodnia Lekarska KOMED

Konin, Poland
Royal Marsden Hospital

Sutton, United Kingdom
START Mountain Region

West Valley City, Utah, 84119, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States
Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Oddział Chemioterapii

Warsaw, Poland
Szpital Woj. im M Kopernika

Koszalin, Poland
UMHAT Sv. Ivan Rilski

Sofia, Bulgaria
UZ GENT

Ghent, Belgium
United Medical Group

Miami, Florida, 33135, United States
University of Virginia Health System Cancer Center

Charlottesville, Virginia, 22903, United States
Vall d' Hebron Institute of Oncology (VHIO)

Barcelona, Spain
Westmead Hospital

Westmead, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.